Searchable abstracts of presentations at key conferences in endocrinology

ea0070aep670 | Pituitary and Neuroendocrinology | ECE2020

Eucaloric very low-carbohydrate ketogenic diet as a new supportive treatment modality for acromegaly?

Coopmans Eva , Berk Kirsten AC , El-Sayed Nour , Neggers Sebastian , Van der Lely Aart Jan

Objective: Acromegaly is caused by a growth hormone (GH)-secreting pituitary tumor and its signs are linked to increasedGH-dependent hepatic insulin-like growth factor I (IGF-I) synthesis. A eucaloric very low-carbohydrate ketogenic diet (euVLCK; < 50 g/day) induces ketosis and reduces portal insulin concentrations, which down-regulate hepatic GH receptors and reduce IGF-I synthesis. Somatostatin receptor ligands (SRLs) reduce GH secretion by the pituitary tumor,resul...

ea0056gp4 | Acromegaly | ECE2018

Efficacy and safety of switching to pasireotide LAR monotherapy or in combination with pegvisomant in acromegaly patients controlled with combination therapy of somatostatin analogues and pegvisomant (PAPE study): a prospective, open-label 48 week study

Coopmans Eva C , Muhammad Ammar , Janssen Joseph AMJL , van der Lely Aart J , Neggers Sebastian JCMM

Background: In the core phase of the PAPE study until 24 weeks we have shown that switching to pasireotide LAR (PAS-LAR) in well-controlled acromegaly patients receiving combination therapy of somatostatin analogues and pegvisomant (PEGV), normalizes IGF1 levels in the majority of patients. PAS-LAR induced a significant PEGV sparing effect, but this was at the expense of a higher incidence of diabetes. This extension study until 48-weeks assesses the efficacy, safety and quali...

ea0070aep660 | Pituitary and Neuroendocrinology | ECE2020

Predictors for remission after transsphenoidal surgery in acromegaly: A dutch multicenter study

Coopmans Eva , Postma Mark , Wolters Thalijn , van Meyel Sebastiaan , Teodora Netea-Maier Romana , Neggers Sebastian , van Beek Andre

Context: Transsphenoidal surgery (TSS) is the primary treatment of choice in acromegaly. It is important to identify patients in whom surgical cure is not attainable at an early stage, both to inform patients on expected treatment outcome and to select those who are more likely to need additional therapy.Objective: To identify predictors for remission and relapse after TSS in acromegaly.Design: Retrospective study in three large te...

ea0056gp6 | Acromegaly | ECE2018

IGF-I response to pasireotide LAR treatment in acromegaly is mainly driven by somatostatin receptor subtype 2 expression

Muhammad Ammar , Coopmans Eva , Gatto Federico , Franck Sanne , Janssen Joseph , van der Lelij Aart Jan , Hofland Leo , Neggers Sebastian

Background: The response to first-generation long-acting somatostatin analogues (LA-SSA) treatment in acromegaly depends on the expression of the somatostatin receptor (SSTR) subtypes. In contrast to octreotide and lanreotide which preferentially bind to SSTR2, pasireotide targets multiple SSTRs, with the highest binding affinity for SSTR5. It has previously been suggested that SSTR5 expression could predict the response to pasireotide LAR (PAS-LAR) treatment in acromegaly.</p...

ea0063oc3.5 | Cushing's and acromegaly | ECE2019

T2-signal intensity, SST receptor expression and first-generation somatostatin analogues efficacy predict hormone and tumor responses to pasireotide in acromegaly

Coopmans Eva C , Schneiders Joppe J , El-Sayed Nour , Muhammad Ammar , Hofland Leo J , Petrossians Patrick , van der Lely Aart. J , JCMM Neggers Sebastian

Background: Previous studies indicate that PAS-LAR can achieve control of insulin-like growth factor I (IGF-I) levels and may reduce tumor size, however a subset of acromegaly patients responds poorly. T2-signal intensity, somatostatin receptor (SST) subtype 2 and 5 expression, and the response to first-generation somatostatin receptor ligands (SRLs) are recognized predictors of therapy response. Valid prediction of the response to PAS-LAR can alter treatment stratification.</...

ea0063gp173 | Obesity (1) | ECE2019

Excellent tumor response to pasireotide therapy in an aggressive and dopamine-resistant prolactinoma

Coopmans Eva , van Meyel Sebastiaan , Pieterman Kay , van Ipenburg Jolique , Hofland Leo , Donga Esther , Daly Adrian , Beckers Albert , van der Lely Aart-Jan , Neggers Sebastian

Background: Prolactinomas are the most frequent secreting pituitary adenomas encountered in the clinical setting. Cabergoline is considered the mainstay medical treatment and transsphenoidal surgery (TSS) is recommended for patients that are medically resistant to dopamine agonist therapy. Resistance to dopamine agonists is commonly defined as failure to normalize prolactin and less than 50% decrease in tumor diameter at a maximal labeled dose of 2.0 mg/week. Pasireotide LAR (...

ea0070aep748 | Pituitary and Neuroendocrinology | ECE2020

Soluble klotho: A possible predictor of quality of life in acromegaly patients

Coopmans Eva , El-Sayed Nour , Frystyk Jan , Erik Magnusson Nils , Otto Jorgensen Jens , Jan Van der Lely Aart , Janssen Joseph AM , Muhammad Ammar , Neggers Sebastian

Purpose: Although quality of life (QoL) is improved in patients with acromegaly after disease control, QoL correlates only weakly with traditional biomarkers. Our objective is to investigate a potential relation between the new serum biomarker soluble Klotho (sKlotho), GH and insulin-like growth factor 1 (IGF-1) levels and QoL.Methods: In this prospective cohort study, we investigated 54 acromegaly patients biochemically well-controlled on combination tr...

ea0073aep839 | Late Breaking | ECE2021

Neuroendocrine neoplasm of the pancreas as a manifestation of familial isolated pituitary adenoma: A case report

Coopmans Eva , Korpershoek Esther , M.F. van Velthuysen , Adrian F. Daly , Beckers Albert , Aart Jan Van der Lely , Neggers Sebastian , Hofland Hans , Feelders Richard , Wouter W de Herder

ContextGermline mutations in the aryl hydrocarbon receptor-interacting protein (AIP) have been identified in patients with pituitary adenomas, most frequently presenting as somatotropinomas in the setting of familial isolated pituitary adenoma (FIPA). Our current understanding of AIP related tumorigenesis indicates that it leads to isolated pituitary adenomans, while other associated tumors have not typically been considered part of the...

ea0067o40 | Oral Presentations | EYES2019

T2-signal intensity, SST receptor expression and first-generation somatostatin analogs efficacy predict hormone and tumor responses to pasireotide in acromegaly

Coopmans Eva C , Schneiders Joppe J , El-Sayed Nour , Erler Nicole S , Hofland Leo J , Petrossians Patrick , van den Berg Sjoerd , van der Lely Aart-Jan , Muhammad Ammar , Neggers Sebastian JCMM

Objective: MRI T2-signal intensity and somatostatin (SST) receptor expression are recognized predictors of therapy response in acromegaly. We investigate the relationship between these predictors and the hormonal and tumor responses to PAS-LAR therapy, and compare to first-generation somatostatin receptor ligands (SRLs) responsiveness.Methods: We included 45 acromegalics initially receiving SRLs, followed by a combination therapy including pegvisomant (P...